MedTrace Logo

The Expression Heparanase in Term and Preterm Placentas

NCT03798964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-06-28

No results posted yet for this study

Summary

Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM).

This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) .

The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.

Conditions

Interventions

OTHER

Placental analysis

Analysis of placenta to determine expression of heparanase

Sponsors & Collaborators

  • Hillel Yaffe Medical Center

    lead OTHER_GOV

Principal Investigators

  • Rinat Gabbay-Benziv, MD · Hillel Yaffe Medical Center

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-23
Primary Completion
2020-11-24
Completion
2020-11-24

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03798964 on ClinicalTrials.gov